[
  {
    "ts": null,
    "headline": "US Equity Indexes Lower Ahead of Fed Policy Decision Despite Robust Retail Sales, Surprise Industrial Production Print",
    "summary": "US equity indexes were lower after close on Tuesday, but were trading close to record levels as the",
    "url": "https://finnhub.io/api/news?id=64d7a718eef6d461e2d1c25ec112182ee782351ea94f568036928f9483e2b952",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758058461,
      "headline": "US Equity Indexes Lower Ahead of Fed Policy Decision Despite Robust Retail Sales, Surprise Industrial Production Print",
      "id": 136787557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "US equity indexes were lower after close on Tuesday, but were trading close to record levels as the",
      "url": "https://finnhub.io/api/news?id=64d7a718eef6d461e2d1c25ec112182ee782351ea94f568036928f9483e2b952"
    }
  },
  {
    "ts": null,
    "headline": "Why Moderna (MRNA) Stock Is Trading Up Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®.",
    "url": "https://finnhub.io/api/news?id=cf96ef5e36f7ef4c079727eb1718b3f7aff25f243313608439755963d70b0008",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758040849,
      "headline": "Why Moderna (MRNA) Stock Is Trading Up Today",
      "id": 136773040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®.",
      "url": "https://finnhub.io/api/news?id=cf96ef5e36f7ef4c079727eb1718b3f7aff25f243313608439755963d70b0008"
    }
  },
  {
    "ts": null,
    "headline": "How Renewed Scrutiny of Pediatric Vaccine Safety at Moderna (MRNA) Has Changed Its Investment Story",
    "summary": "In early September 2025, news emerged that Trump administration health officials planned to present claims linking COVID-19 vaccines to the deaths of about two dozen children, prompting heightened regulatory and public scrutiny of Moderna’s vaccine safety, as well as anticipated CDC advisory committee discussions and possible new vaccine eligibility restrictions. Moderna responded by reaffirming the safety of its Spikevax COVID-19 vaccine, citing worldwide regulatory surveillance, more than...",
    "url": "https://finnhub.io/api/news?id=f0863294438135a79400de030c6e15f237daf025ca50fe51e2854580b6f99805",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024394,
      "headline": "How Renewed Scrutiny of Pediatric Vaccine Safety at Moderna (MRNA) Has Changed Its Investment Story",
      "id": 136774053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In early September 2025, news emerged that Trump administration health officials planned to present claims linking COVID-19 vaccines to the deaths of about two dozen children, prompting heightened regulatory and public scrutiny of Moderna’s vaccine safety, as well as anticipated CDC advisory committee discussions and possible new vaccine eligibility restrictions. Moderna responded by reaffirming the safety of its Spikevax COVID-19 vaccine, citing worldwide regulatory surveillance, more than...",
      "url": "https://finnhub.io/api/news?id=f0863294438135a79400de030c6e15f237daf025ca50fe51e2854580b6f99805"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans",
    "summary": "Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula ...",
    "url": "https://finnhub.io/api/news?id=90dbe72919252acffea8e313f1630ceac40b8e866821e789e4439fdf7adde50f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758020400,
      "headline": "Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans",
      "id": 136774054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data supporting recent FDA approval of 2025-2026 formula ...",
      "url": "https://finnhub.io/api/news?id=90dbe72919252acffea8e313f1630ceac40b8e866821e789e4439fdf7adde50f"
    }
  }
]